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Abstract
Background: Recent data indicate that excitotoxicity of high levels of neurotransmitter glutamate
may be mediated via programmed cell death (apoptosis) and that it can be prevented in HT22
mouse hippocampal cells by various equine estrogens with ∆8,17β-estradiol (∆8,17β-E2) being the
most potent. In order to delineate the mechanism(s), glutamate-induced cell death of HT22 cells
was assessed by measuring (a) DNA fragmentation in the presence or absence of 11 equine
estrogens (components of the drug CEE); (b) cell death and (c) levels of anti-apoptotic (Bcl-2) and
proapoptotic (Bax) proteins in the presence or absence of two equine estrogens, ∆8,17β-E2 and
17β-estradiol (17β-E2) by LDH release assay and Western blot analysis respectively.
Results: Glutamate treatment induced cell death was time and dose-dependent. After 18 to 24 h,
glutamate induced DNA fragmentation and morphological characteristics of apoptotic cell death.
DNA fragmentation and morphological changes induced by 10 mM glutamate were completely
inhibited by some equine estrogens. Exposure of cells to various concentrations of glutamate,
resulted in a significant increase in cell death associated LDH release that was time-dependent.
Both ∆8,17β-E2 and 17β-E2 inhibited the glutamate-induced LDH release and cell death in a dose-
dependent manner with ∆8,17β-E2 being 10 times more potent than 17β-E2. Western blot analysis
indicated that glutamate also significantly decreased the levels of Bcl-2 and increased Bax levels.
This glutamate-induced change in the ratio of Bcl-2 to Bax was reversed by estrogens with ∆8,17β-
E2 being more potent.
Conclusions: In HT22 mouse hippocampal cells, glutamate induced apoptosis that was associated
with DNA fragmentation, morphological changes and up-regulation of the pro-apoptotic protein
Bax and down-regulation of the anti-apoptotic protein Bcl-2. This apoptotic process was
differentially prevented by some equine estrogens with ∆8,17β-E2 being more potent than 17β-E2.
Since HT22 cells lacked both glutamate and estrogen receptors, the neuroprotective effects of
estrogens most likely involve both genomic and non-genomic mechanisms. Since ∆8-estrogens are
less feminizing estrogens than 17β-E2, further chemical modifications of these ∆8-estrogens may
provide more selective estrogens that will be useful in the prevention of neurodegenerative
diseases such as Alzheimer's and Parkinson's in both aging men and women.
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Background
High concentrations (mM) of the excitatory neurotrans-
mitter glutamate can accumulate in the brain and are
thought to be involved in the etiology of a number of neu-
rodegenerative disorders including Alzheimer's disease [1-
4]. A number of invitro studies indicate that at high con-
centrations, glutamate is a potent neurotoxin capable of
destroying neurons maintained in tissue culture [5-10].
The mechanisms by means of which glutamate-induced
neurotoxicity or excitotoxicity is mediated are not fully
understood, however, a substantial body of evidence sug-
gests that glutamate toxicity involves oxidative stress and
programmed cell death (apoptosis) [2,11]. This form of
cell death is characterized by DNA degradation that results
by cleaving DNA at internucleosomal sites by endonucle-
ases [12]. A number of studies have demonstrated that
estrogens are potent anioxidants that may inhibit some of
the neurotoxic effects of oxidative stress [7,13-15].
Recently, we reported that neurotoxic effects of oxidized
LDL can be differentially inhibited by equine estrogens
with the novel ∆8-estrogens being the most potent neuro-
protectors [16]. Oxidative stress has been implicated in
neurodegenerative diseases such as Alzheimer's disease
[17], Parkinson's disease [2,18] and observational studies
indicate that exogenous estrogen use by healthy postmen-
opausal women can either reduce the risk or delay the
onset of Alzheimer's disease [19-23]. We and others,
[7,13-17,24] have demonstrated that estrogens are potent
antioxidants. Furthermore, we [15,16,24] also demon-
strated that equine estrogens differed extensively in their
neuroprotective potencies in both estrogen receptors ER
positive (PC12 cells) and ER negative (HT22) neuronal
cell lines. Moreover, the neuroprotective potencies did not
correspond to their binding affinities for human ERα and
ERβ [25]. Since HT22 cells lack both ERs and ionotropic
glutamate receptors [6,7,13], high concentrations of
glutamate kills these cells via oxidative pathway [26,27].
Therefore, to gain insight into the cellular mechanisms
involved in the differential inhibition of glutamate toxic-
ity by various equine estrogens, we selected HT22 cell line
as a model for neuronal cells. The objective of the present
study is to delineate the mechanism(s) involved in the
neuroprotective effects of estrogens in the glutamate-
induced cell death. We hypothesize that equine estrogens
by an ER-independent mechanism prevent glutamate-
induced programmed cell death by inhibiting DNA frag-
mentation and modulating levels of anti-apoptotic and
pro-apoptotic proteins, Bcl-2 and Bax, respectively, that
are known to play a key role in cell life and death [28-30].
Results
Apoptosis in HT22 cells treated with glutamate
HT22 cells were harvested between 18 or 24 h after gluta-
mate (5 to 20 mM) incubation and total DNA was
extracted, purified and subjected to agarose gel electro-
phoresis. The results indicate that cells cultured in the
absence (control) of glutamate did not induce any DNA
fragmentation (Figure 1A, Lane 2). In contrast, glutamate
induced characteristic DNA fragmentation or laddering in
a dose-dependent manner, (Figure 1A, Lanes 3–5). The
extent of fragmentation was similar between 18 h, (Figure
1A, Lane 6) and 24 h, (Figure 1A, Lane 4). All subsequent
DNA fragmentation experiments were carried out for 18 h
and in the presence of 10 mM glutamate. Addition of var-
ious equine estrogens (10 µM) resulted in complete inhi-
bition of DNA fragmentation with only 17α-Eqn (Figure
1B, Lane 7), ∆8-E1 (Figure 1B, Lane 8), and ∆8,17β-E2 (Fig-
ure 1C, Lane 8). The remaining eight estrogens including
17β-E2 were ineffective at this dose of estrogen (Figure 1B,
Lanes 1, 4–6 and Figure 1C, lanes 4–7) in preventing DNA
fragmentation induced by 10 mM glutamate. Glutamate-
induced apoptotic cell death was also detectable by char-
acteristic morphological changes observed by using phase
contrast microscopy (Figure 2). After an 8 hr incubation
with 8 mM glutamate, dead cells were clearly visible in the
cultures (Figure 2B), and the cellular extension (den-
drites) seen in untreated HT22 cells (Figure 2A), were
retracted, and cells appeared rounded and detached.
Degenerated cells were also clearly visible (Figure 2B). In
the presence of 8 mM glutamate and 10 µM ∆8,17β-E2, the
cells (Figure 2C) retained the morphology of untreated
cells and degenerated cells were absent. In contrast, in the
presence of 10 µM 17β-E2, the cells have the appearance
of cells treated with 8 mM glutamate alone and a large
number of dead cells were visible (Figure 2D). These
results clearly indicate that ∆8,17β-E2 was able to prevent
glutamate induced cell death while the same amount of
17β-E2 was not protective. However, when the cells were
treated with 5 mM glutamate for 18 h, the extent of cell
death was less (Figure 2E) and under these conditions, the
morphological changes and cell death induced by gluta-
mate was also preventable by 10 µM 17β-E2 (Figure 2F).
Effects of glutamic acid and estrogens on cell death
In order to follow the kinetics of glutamate cytotoxicity,
HT22 cells were cultured in 6-well plates (2 × 105 cells/
well) for 24 h. The medium was then changed and the
effects of 10 mM glutamate on LDH release as a function
of time were measured for up to 18 h. The results shown
in Figure 3 indicate that glutamate toxicity varied mark-
edly during the course of cultures. Significant increase (2
to 3 fold) in cytotoxicity was noted after 8 h to 18 h expo-
sure of cells to glutamate. LDH release in untreated con-
trol cells remained essentially unchanged over the 18 h
period (Figure 3). We next determined the effect ofBMC Neuroscience 2003, 4 http://www.biomedcentral.com/1471-2202/4/32
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increasing concentration of glutamate on cell death. As
shown in Figure 4, exposure of cells to 7 to 10 mM gluta-
mate for 8 h resulted in a significant increase in LDH
release compared to the control cells. Lower concentra-
tion (5 mM) of glutamate over a period of 8 h had no det-
rimental effect on the cells. However, exposure to 5 mM
glutamate for 18–20 h also resulted in a significant 2 fold
increase in LDH release (Figure 5).
Based on DNA fragmentation data, two estrogens: 17β-E2
and  ∆8,17β-E2  were tested to investigate the effect of
equine estrogens on glutamate-induced cell death. In
these experiments, HT22 cells were cultured in the pres-
ence of 5 mM glutamate for 18–20 h in the presence or
absence of various concentrations of the two estrogens.
Release of LDH from cells was measured and the results
are depicted in Figure 5. Both 17β-E2 and ∆8,17β-E2 inhib-
ited the glutamate-induced cell death in a dose-dependent
manner, however, ∆8,17β-E2 was 10 times more potent.
Thus 0.1 µM  ∆8,17β-E2 and 1 µM 17β-E2 significantly
reduced the release of LDH compared to glutamate alone.
Higher concentrations of ∆8,17β-E2 (1 µM) and 17β-E2
(10 µM) completely inhibited the glutamate-induced cell
death and the LDH release returned to control values (Fig-
ure 5). When cells were exposed for 8 h to higher concen-
trations of glutamate (7–8 mM), only ∆8,17β-E2 was able
to significantly inhibit glutamate-induced cell death and
return the LDH release to control values. However, under
these conditions, higher concentration (10 µM) of
∆8,17β-E2 was needed. In contrast, 17β-E2 had no signifi-
cant effect on cell death induced by this concentration of
glutamate (Figure 6).
Effect of glutamic acid and estrogen on Bcl-2 and Bax 
protein levels
Following the measurement of LDH in the medium, the
cells treated with glutamate were processed for Western
blot analysis as described under "Methods". The results
indicate that levels of Bcl-2 decreased significantly while
those of Bax increased significantly between 7 to 10 mM
glutamate within 8 h, (Figure 7). Thus, 7 and 10 mM
glutamate decreased Bcl-2 protein levels by 30 and 45%
respectively, while Bax protein levels increased by 20 to
25% respectively (Figure 7). No change in Bcl-2 and Bax
levels were observed in the presence of 5 mM glutamate
for 8 h, (Figure 7). However, after 18–20 h exposure to 5
mM glutamate, the protein levels of Bcl-2 decreased and
those of Bax increased (Figure 8). These results clearly
Detection of glutamate (5 to 20 mM) induced DNA fragmentation (DNA ladder) and its prevention by some equine (10 µM)  estrogens Figure 1
Detection of glutamate (5 to 20 mM) induced DNA fragmentation (DNA ladder) and its prevention by some equine (10 µM) 
estrogens. A: Lane: 1 = 1 kb DNA ladder; 2 = control HT22 DNA; 3 = 5 mM glutamate; 4 = 10 mM glutamate; 5 = 20 mM 
glutamate; 6 = 10 mM glutamate (18 h). B: HT22 cells treated with 10 mM glutamate for 18 h in presence or absence of estro-
gens. Lane: 1 = 17α-E2; 2 = control; 3 = 10 mM glutamate; 4 = 17β-E2; 5 = Eq; 6 = 17β-Eqn; 7 = 17α-Eqn; 8 = ∆8-E1. C: Lane: 1 
= 1 kb DNA ladder; 2 = control; 3 = 10 mM glutamate alone; 4 = E1; 5 = Eqn; 6 = 17β-Eq; 7 = 17α-Eq; 8 = ∆8,17β-E2. Gel elec-
trophoresis was carried out as described under methods and the gels were stained with ethidium bromide.BMC Neuroscience 2003, 4 http://www.biomedcentral.com/1471-2202/4/32
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Glutamate-induced toxicity in mouse hippocampal HT22 cells as assessed by phase contrast microscopy (200×) Figure 2
Glutamate-induced toxicity in mouse hippocampal HT22 cells as assessed by phase contrast microscopy (200×). HT22 cells 
were cultured and treated with glutamate alone or in the presence of estrogens for 8 to 18 h. Degenerated cells are depicted 
by arrows. A = Untreated control cells; B = 10 mM glutamate; C = 10 mM glutamate + 10 µM ∆8,17β-E2; D = 8 mM glutamate 
+ 10 µM 17β-E2; E = cells treated with 5 mM glutamate for 18 h; F = 5 mM glutamate + 10 µM 17β-E2 for 18 h.BMC Neuroscience 2003, 4 http://www.biomedcentral.com/1471-2202/4/32
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indicate that glutamate modulates apoptotic pathways by
inducing changes in anti-apoptotic and pro-apoptotic
factors. These glutamate-induced changes were reversed in
the presence of estrogens. Thus, increasing concentrations
of 17β-E2 in the presence of 5 mM glutamate for 18–20 h,
increased the levels of Bcl-2 and decreased the Bax protein
in a dose-dependent manner (Figure 8). As can be seen, 1
µM to 10 µM 17β-E2  reversed the glutamate-induced
changes and the levels of Bcl-2 proteins returned to con-
trol values with 10 µM 17β-E2  (Figure 8). Similarly,
increasing concentrations of ∆8,17β-E2 in the presence of
7–8 mM glutamate for 8 h increased the levels of Bcl-2 in
a dose-dependent manner (Figure 9). At a concentration
of 0.1 µM, ∆8,17β-E2, the levels of Bcl-2 increased by 25–
35% over the glutamate alone levels (Figure 9). In con-
trast, the levels of Bax decreased significantly only at the
highest (10 µM) concentration of ∆8,17β-E2 (Figure 9). At
this concentration of glutamate (7–8 mM), the changes in
levels of Bcl-2 and Bax were not reversible by 17β-E2 (Fig-
ure 10). Estrogen in absence of glutamate did not alter the
control values of both Bcl-2 and Bax (data not shown).
Discussion
In this study, we used clonal mouse hippocampal cell line
HT22 in culture, to test the hypothesis that glutamate can
induce neuronal cell death by apoptotic mechanisms and
that this process can be inhibited or reversed by some
novel equine estrogens. Our results clearly indicate that
glutamate-induced cell death results via a mechanism that
involves DNA fragmentation characteristics of apoptosis.
Glutamate-induced DNA fragmentation in HT22 cells was
dose-dependent and maximal fragmentation occurred
between 18 to 24 h in the presence of 10 mM glutamate.
At glutamate concentrations below 10 mM, DNA frag-
mentation was not clearly visible most likely due to the
lack of sensitivity of the method. Our results in general,
are in keeping with a previous study, where similar DNA
fragmentation was observed in HT22 cells that had been
treated with glutamate [7]. A number of studies suggest
that formation of large molecular weight DNA fragments
is a committed step in the apoptotic cell death process
[30-32], however, in the present study only the subse-
quent late event of apoptosis characterized by low molec-
ular weight DNA fragmentation (DNA ladder) was
measured. Although this form of DNA fragmentation is a
Kinetics of glutamate-induced cell death in HT22 cells Figure 3
Kinetics of glutamate-induced cell death in HT22 cells.
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late event in apoptosis, it is considered to be one of the
characteristic features of apoptosis [33] and is not seen in
necrotic cell death. The formation of DNA ladders was
completely blocked by 3 equine estrogens: 17α-Eqn, ∆8-E1
and ∆8,17β-E2. The remaining 8 estrogens tested did not
inhibit the DNA fragmentation at the concentrations
used. These results indicate that under the experimental
conditions of our study, the most potent endogenous
estrogen in human 17β-E2, which has the highest affinity
for ERα and ERβ [25,34], was ineffective in preventing
DNA degradation induced by 10 mM glutamate over a
period of 24 h.
In contrast, we have previously reported [24] that all
eleven estrogens differentially prevented glutamate-
induced cell death in HT22 cells. However, the concentra-
tion of glutamate used in that study were relatively low
(LD50 1.8 mM). At these low concentrations (<10 mM),
low levels of DNA fragmentation occurs but the laddering
was difficult to visualize (Figure 1A, Lane 3). It is there-
fore, probable that the ineffectiveness of some estrogens
to prevent DNA fragmentation induced by 10 mM or
higher concentrations of glutamate may be due to a much
higher number of cells were undergoing apoptotic cell
death and thus exhibited DNA fragmentation. At these
high concentrations of glutamate, cell death was greater
than 50% as measured by LDH release assay and under
these conditions, only 3 of the 11 estrogens were able to
prevent or inhibit this process; This LDH data will be dis-
cussed later.
The mechanism by means of which large molecular
weight DNA fragmentation occurs has not been fully
delineated, however, it has been postulated that specific
endonucleases, DNase I and/or DNase II may be involved
in this process [35-38]. It has also been shown that the
enzyme activity required for high molecular weight DNA
fragmentation during drug-induced apoptosis may exist
as a proendonuclease that is converted to an active form
by the action of cysteine protease [38]. Whether estrogens
can inhibit this activation and thereby prevent apoptosis,
remains to be investigated.
Effect of various concentration of glutamate on cell death in HT22 cells Figure 4
Effect of various concentration of glutamate on cell death in HT22 cells. LDH release was measured after an 8 h treatment. *P 
< 0.05 vs untreated control cells.
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The glutamate-induced DNA fragmentation and subse-
quent cell death was also confirmed by morphological
changes observed by phase contrast microscopy. Similar
observations have been reported in cell death induced by
glutamate and amyloid β-protein in rat primary hippoc-
ampal neurons and HT22 cells [39]. Our results further
extend those observations by demonstrating that the mor-
phological changes induced by glutamate were prevented
by ∆8,17β-E2 and 17β-E2 (Figure 2). This morphological
data also indicates that ∆8,17β-E2 was more potent than
17β-E2. Although we have previously reported that the
neurotoxic effects of oxidized LDL [16] and glutamate
[24] are inhibited differentially by various estrogens, the
results from the present study are, to our knowledge, the
first observations whereby estrogens also have differential
effects in preventing low molecular weight DNA fragmen-
tation and morphological changes associated with
apoptosis.
To quantitatively estimate the extent of cell death induced
by glutamate, we measured the LDH activity released in
media during culture of cells [7,40]. This assay has been
further validated by us, using the MTS (3-[4,5-dimethylth-
iazol-2 yl]-5 [3-carboxymethoxy phenyl]-2H tetrazolium,
inner salt) cell proliferation assay, which measures the
number of viable cells [24]. The results of these LDH
measurements indicate that neurotoxicity induced by
glutamate was both time and concentration dependent.
The release of LDH induced by 5 mM glutamate was com-
pletely inhibited by 1 µM ∆8,17β-E2 and 10 µM 17β-E2. At
lower concentrations, 0.1 and 1 µM, these two estrogens
also significantly protected the cells from glutamate
induced cell death. This differential neuroprotective effect
of estrogens was also previously reported by us using oxi-
dized LDL as the neurotoxic agent [16]. In contrast to our
observations, and those of others [41], an earlier study
[10] reported that glutamate was unable to induce cell
death of HT22 cells and the authors ascribed this failure
to the absence of glutamate receptors in these cells. How-
ever, the authors have indicated their failure to observe
the toxic effects of glutamate were most likely due to the
presence of the potent antioxidant glutathione in their
Effect of various concentrations of 17β-E2  and 8, 17β-ε2 on glutamate (5 mM) induced cell death Figure 5
Effect of various concentrations of 17β-E2  and 8, 17β-Ε2 on glutamate (5 mM) induced cell death. LDH release was measured 
after 18 h treatment a = P < 0.05 vs untreated control cells; b = P < 0.05 vs glutamate alone treated cells.
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culture medium (RPMI-1640). This is of particular
importance as glutamate neurotoxicity appears to involve
at least two pathways: excitotoxicity which is mediated via
the glutamate receptors, and oxidative glutamate toxicity
which is mediated via inhibition of cystine uptake into the
cell through the cystine/glutamate antiporter [3,42]. This
process under physiological conditions, carries cystine
into the cells and glutamate out. The lack of cystine leads
to depletion of intracellular antioxidant glutathione
(cysteine containing tripeptide) crucial for cell survival
[26]. Thus, inclusion of glutathione in the culture media
could have protected the HT22 cells from oxidative stress
and cell death induced by glutamate [26,43].
In order to investigate the biochemical mechanisms
responsible for glutamate-induced cell death, we are in
this report, presenting data demonstrating that in HT22
cells, glutamate significantly decreases the expression of
the antiapoptotic protein Bcl-2 and increases the levels of
proapoptotic protein Bax in a dose and time-dependent
manner. Since the HT22 hippocampal cells that we used
in our study lack ionotrophic glutamate receptors, neuro-
nal cell death induced by glutamate is most likely medi-
ated via the "oxidative pathway" [26,27,43] that involves
reactive oxygen species (ROS). This type of ROS-induced
neuronal death has also been previously observed in β-
amyloid, nerve growth factor or serum deprivation-
induced apoptosis [2,11,26,27,44,45]. Thus, in HT22
cells, our results together with those of others indicate that
the mechanism involved for induction of cell death and
its prevention, was independent of both glutamate and
estrogen receptors, and most likely, involved modulation
of free radical mediated oxidative damage [2,3,6,11,27].
We have previously reported that a number of equine
estrogens that are components of the drug CEE (Premarin,
Wyeth Pharmaceuticals, USA, Canada) used extensively
for management of vasomotor symptoms and osteoporo-
sis in postmenopausal women, are potent antioxidants
[15] and protect neuronal cells against cell death induced
by oxidized LDL and glutamate [16,24,43,46]. The results
from the present study indicate that these equine
Effect of various concentrations of 17β-E2 and ∆8,17β-E2 on glutamate (7–8 mM) induced cell death Figure 6
Effect of various concentrations of 17β-E2 and ∆8,17β-E2 on glutamate (7–8 mM) induced cell death. LDH release was measured 
after 8 h treatment. a = P < 0.05 vs untreated control; b = P < 0.05 vs glutamate alone treated cells.
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estrogens prevent cell death and changes in the levels of
two key proteins Bcl-2 and Bax induced by glutamate.
Specifically, we show that glutamate-induced decrease in
the expression of antiapoptotic protein Bcl-2 and an
increase in the levels of proapoptotic protein Bax was
reversed by estrogen. Since HT22 cells also lack the pres-
ence of estrogen receptors [7], our data strongly suggest
that the estrogen mediated regulation of apoptosis in our
model system does not involve the classic estrogen tran-
scriptional regulation. Thus, estrogen-reversed glutamate
induced reduction in Bcl-2 protein expression and this
was accompanied by increased neuronal cell survival. This
estrogen-induced process may involve a non-genomic
mechanism in HT22 neuronal cells.
In contrast to our results, previous studies [46] in primary
cultures of rat fetal hipocampal neurons, β-amyloid-
induced neuronal cell death was inhibited by estrogen via
the estrogen receptor mediated transcriptional up-regula-
tion of Bcl-xl. However, other studies using either primary
culture of rat fetal cortical neurons or HT22 cells, showed
that the estrogen protective effect against glutamate
toxicity, was mediated via a pathway not involving estro-
gen receptors [7,10]. These observations suggest that
estrogens' neuroprotective effects can involve both
genomic and non-genomic mechanisms, that depend on
the neuronal cell type and the cytotoxin used to induce
apoptosis. With oxidized LDL and glutamate as neuro-
toxic agents, all estrogens tested were neuroprotective,
however, the potency was variable [16,24] in that the
novel ∆8-equine estrogens were several times more potent
than 17β-E2. The results from the present study also indi-
cate that ∆8,17β-E2 was able to prevent glutamate-induced
neuronal cell damage at doses that were 10 times lower
than those of 17β-E2. These observations suggest that the
presence of an isolated double bond between carbon
positions 8 and 9 significantly increases the neuroprotec-
tive activity of estrogens.
Effect of various concentrations of glutamate on Bcl-2 and Bax protein levels in HT22 cells treated for 8 h Figure 7
Effect of various concentrations of glutamate on Bcl-2 and Bax protein levels in HT22 cells treated for 8 h. Western analysis 
was carried out as described under Methods and the blots are shown in the upper right hand corner. The bars depict densit-
ometry analyses of Western Blots from three independent experiments. (± SEM). Note the significant decrease in Bcl-2 levels 
and increase in Bax levels following exposure of cells to glutamate; * P < 0.05 vs untreated control cells.
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A number of other mechanisms have been proposed to
explain how estrogens may influence neuronal survival
and some of these are: estrogens can alter cellular calcium
which may play a role in glutamate cytotoxicity, alter syn-
aptogenesis by interactions with the NMDA receptors, and
phosphorylate cAMP (cyclic adenosine monophosphate)
response element binding protein (CREB) leading to neu-
ronal protection [48-50] and these have been recently dis-
cussed [24].
Since the Bcl family of proteins is made up of a group of
apoptosis regulatory genes of which Bcl-2 and Bcl-xl are
antiapoptotic, whereas Bax, Bcl-xs, Bad, Bak, and Bik are
proapoptotic, the ratio of Bcl-2 to Bax will determine
whether the cells will undergo apoptotic cell death or sur-
vive the death insult. Our results suggest that perhaps a
key mechanism by means of which equine estrogens pro-
tect HT22 neuronal cell death is by altering this ratio in
favor of Bcl-2 i.e. increase in the antiapoptotic regulatory
gene concomitant with a decrease in the expression of
proapoptotic genes.
Along with Bcl-2 and Bax, other mitochondrial proteins
are known to play a key role in mammalian cell apoptosis
and a number of mitochondrial proteins, appear to be
able to activate the apoptotic process directly [51,52].
Among these are two proteins: apoptosis inducing factor
(AIF), and endonuclease G (Endo G) that are released in
response to death signals and appear to execute apoptosis
and kill cells in a caspase-independent fashion. Both AIF
and Endo G can enter the cell nuclei and cause chromatin
condensation and large scale fragmentation of DNA [53-
55]. Like the release of mitochondrial cytochrome C,
these two apoptogenic proteins appear to be regulated by
the Bcl-2 family of proteins [52,56]. Whether the inhibi-
tion of glutamate induced apoptosis by estrogens
observed in our study is mediated by changes in the
release of cytochrome C, AIF and Endo G, remains to be
investigated. Interestingly, since we observed the
Effect of various concentrations of 17β-estradiol on Bcl-2 and Bax protein levels in HT22 cells treated with 5 mM glutamate for  18 h Figure 8
Effect of various concentrations of 17β-estradiol on Bcl-2 and Bax protein levels in HT22 cells treated with 5 mM glutamate for 
18 h. Western blots are shown on the upper right hand corner and the bars depict densitometry analysis. Note that the gluta-
mate-induced changes (cell death) in Bcl-2 and Bax are reversed in the presence of 17β-estradiol. a = P < 0.05 vs untreated 
control cells. b = P < 0.05 vs glutamate alone treated cells.
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oligonucleosomal DNA fragmentation (Figure 1), a
process that is known to be necessary for Bax-induced cell
death and is thought to be entirely dependent on caspase-
3 activated DNAse, whether this protease is present in
HT22 cells is being investigated.
It has been demonstrated that Bax-induced cell death may
not require caspase-3 like protease activity [57]. In this cell
death pathway Bax induces changes in mitochondrial
function that ultimately result is known in cell death inde-
pendent of known interleukin 1β-converting enzyme
(ICF)-like cysteine proteases such as caspase-3 [57]. Bax
has also been shown to induce mitochondrial cytochrome
C release into the cytosol followed by rapid activation of
caspases causing cell death [58]. Whether equine estro-
gens protective effects are mediated by alterations in mito-
chondrial function is under investigation.
Conclusions
The results of our study indicate that in HT22 mouse hip-
pocampal cells glutamate induces apoptosis that is associ-
ated with DNA fragmentation and upregulation of the
proapoptotic protein Bax and down-regulation of the
antiapoptotic protein Bcl-2. This apoptotic process can be
differentially prevented by two equine estrogens with the
∆8-estrogen being more potent than the classic estrogen
17β-E2. Interestingly, these ∆8-estrogens are less feminiz-
ing estrogens than the classic estrogen 17β-E2. Further
chemical modifications of these ∆8-estrogens may provide
more selective estrogens that will be useful in the preven-
tion of neurodegenerative diseases such as Alzheimer's
disease and Parkinson's disease in both genders.
Methods
Materials
Rabbit polyclonal antibodies to Bcl-2 (N-19:SC492), and
Bax (N-20:SC493) and goat polyclonal antibody to actin
Effect of various concentrations of ∆8,17β-estradiol on Bcl-2 and Bax protein levels in HT22 cells treated with 7–8 mM gluta- mate for 8 h Figure 9
Effect of various concentrations of ∆8,17β-estradiol on Bcl-2 and Bax protein levels in HT22 cells treated with 7–8 mM gluta-
mate for 8 h. Western blots are shown on the upper right hand corner and the bars depict densitometry analysis. Note that 
the glutamate-induced changes (cell death) in Bcl-2 and Bax are reversed in the presence of ∆8,17β-estradiol. a = P < 0.05 vs 
untreated control cells. b = P < 0.05 vs glutamate alone treated cells.
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(I-19:SC1616) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, U.S.A.) All other antibod-
ies were from Sigma (Toronto, On. Canada). Super Signal
West Pico Chemiluminescent substrate was obtained
from Pierce (Rockford, Il, U.S.A.). The Cytotox 96 Non-
radioactive Cytotoxicity Assay Kit (Promega G1780) was
purchased from VWR (Toronto, Ontario, Canada).
Cell culture and experimental conditions
The mouse hippocampal cell line (HT22) were grown
essentially as described previously [16]. Briefly, HT22 cells
were grown initially in 75 cm2 (250 mL) flasks using Dul-
becco's Modified Eagle Medium (DMEM, Sigma, Toronto,
Canada) containing 4.5 g glucose/L, 50,000 U penicillin/
L (Invitrogen, Burlington, On. Canada), 75 mg/L Strepto-
mycin/L (Invitrogen), 1.5 g sodium bicarbonate/L, 10
mM Hepes, 5% horse serum and 10% fetal bovine serum.
During the developmental phase of methods, experi-
ments were carried out using both untreated serum or
charcoal stripped serum (free of estrogens and other ster-
oids) and no difference was observed in the rate of growth
or the maintenance of these cells. Similarly, addition of
estrogen alone did not affect HT22 cell proliferation
under the experimental conditions used. All experiments
were subsequently carried out using untreated serum and
in media containing phenol red. This serum may contain
trace amounts of glutamate, the actual concentrations of
glutamate indicated has not been corrected. Since the
results are expressed in terms of changes against the con-
trol, the overall results and conclusions are not affected.
Cells were maintained at 37C in 5% carbon dioxide
atmosphere. Exponentially, growing cells were plated on
6 well plates at 2 × 105 cells per well. After 24 h, medium
was changed and cells were treated with various concen-
trations (5 to 20 mM) of glutamate in presence or absence
of estrogens. At various times (3 to 18 h), the cell death
was determined by the LDH (lactate dehydrogenase) cyto-
toxicity assay. At glutamate concentration of 8 mM,
approximately 40 to 50% of cell death occurred in 8 h.
Lack of an effect of 17β-estradiol on Bcl-2 and Bax protein levels in HT22 cells treated with 7–8 mM glutamate for 8 h Figure 10
Lack of an effect of 17β-estradiol on Bcl-2 and Bax protein levels in HT22 cells treated with 7–8 mM glutamate for 8 h. West-
ern blots are shown on the upper right hand corner and the bars depict densitometry analysis. Note that the glutamate-
induced changes in Bcl-2 and Bax are not reversed by 17β-estradiol in the presence of glutamate. a = P < 0.05 vs untreated 
control.
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Western blot analysis
Protein levels of Bcl-2, and Bax were determined by West-
ern blotting using standard protocols. In brief, cells were
washed with cold PBS, harvested using a cell scraper, and
lysed in buffer (9 mM Na2Po4, 1.7 mM NaHPO4 and 150
mM NaCl, pH 7.4), containing 1% Nonidet P-40 (Sigma),
0.5% sodium deoxycholate, 0.1% SDS and 1 mM phenyl
methyl sulfonyl fluoride for 20 min on ice. Cell lysates
were centrifuged at 10,000 g for 10 min at 4C and the pro-
tein content was determined by the Bradford method
(BioRad, Toronto, On, Canada). Lysates containing 15 to
25 µg of protein were added in equal volume of 2 × reduc-
ing sample buffer (100 mM Tris-HCl, pH 6.8, 200 mM
dithiothretiol, 4% SDS, 20% glycerol, and 0.2%
bromophenol blue). Samples were electrophoresed on
12% polyacrylamide gels under constant current (14–15
mA), and then electrotransferred to Protan nitrocellulose
membrane (Schleicher and Schuell Inc. Keene NH, USA).
The membranes were blocked with 5% non-fat milk in
TBST (20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.05%
Tween 20) at 4C overnight and then incubated with pri-
mary antibody for 1–2 h at room temperature, washed
three times with TBST and incubated (1–2 h) with appro-
priate horse radish peroxidase (HRP)-conjugated second-
ary antibody (Sigma, Toronto, On, Canada). The
membranes were washed three times with TBST and the
immunoblots were visualized on x-ray films after expo-
sure to enhanced chemiluminescence reagents (ECL,
Amersham, Toronto, On. Canada). Actin bands were
monitored on the same blot to verify the consistency of
protein loading. Briefly, the immunoblots were stripped
with TBST containing 0.04% sodium azide for 30 minutes
at room temperature. The blots were probed with anti-
actin primary antibody and appropriate secondary
antibody (anti-goat) as described above. The band inten-
sity was determined from scanned images using UN-
SCAN IT Gel Automated Digitizing System, Version 5.1
(Silk Scientific, Inc, Orem, Utah, USA), software. Each
experiment was repeated at least 3 times and the com-
bined data were compared using the Student's paired t-
test.
Assessment of apoptosis by DNA fragmentation
Apoptotic cells often produce a unique ladder made up of
nucleotide fragments which can be easily visualized by
DNA-agarose gel electrophoresis. We have therefore used
DNA fragmentation as the criteria for apoptotic cell death
and this was determined by modification of previously
described procedures [59]. Briefly, HT22 cells. 5 × 105
were cultured in 8.5 cm Petri dishes for 24 h. in 8 mL of
medium. Various concentrations of glutamate (5–20
mM) were added in the presence or absence of various
concentrations of equine estrogens: (10 µM) estrone (E1),
17β-estradiol (17β-E2), 17α-estradiol (17α-E2), equilin
(Eq), 17β-dihydroequilin (17β-Eq), 17α-dihydroequilin
(17α-Eq), equilenin (Eqn), 17β-dihydroequilenin (17β-
Eqn), 17α-dihydroequilenin (17α-Eqn), ∆8-estrone (∆8-
E1), and ∆8,17β-estradiol (∆8,17β-E2) for 18 h. The cell
monolayers were washed twice with ice cold TBS (20 mM
Tris-HCl, pH 7.6, 137 mM NaCl) and then scraped off the
dish with a policeman and transferred with 1.5 mL TBS
into a centrifuge tube. The cell suspension was centrifuged
at 1500 g for 10 minutes at 4C. The cell pellet was resus-
pended in TBS and recentrifuged. The cells were lysed in
buffer (10 mM Tris·HCl, pH 8.0, 0.1 M EDTA, 20 µg/mL
pancreatic RNAase and 0.5% SDS). The mixture was incu-
bated for 1 h. at 37C and to the viscous solution, protein-
ase K (100 µg/mL) was added and incubated for 3 h. at
50C. After cooling to room temperature, the solution was
extracted with phenol and chloroform and DNA precip-
ited with ethanol. The DNA (5 µg) was loaded onto 1.5%
TBE agarose gel and electrophoresed for 1.5 h at 100 V.
The DNA fragments were visualized by staining with
ethidium bromide and pictures of the gels were taken
under UV transillumination. Each experiment was
repeated at least three times.
Determination of glutamate-induced cell cytotoxicity
Cell death was measured by the Cytotox 96 Assay kit
which quantitatively measures the release of lactate dehy-
drogenase into the medium following cell lysis or cell
death. This assay was used as described by the manufac-
turers. The results are expressed as a percentage of maxi-
mal LDH released following lysis with 0.1% Triton X-100.
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